Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],2.75,1270,DB01175,Escitalopram
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],1.95,1271,DB01175,Escitalopram
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,140",1272,DB01175,Escitalopram
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,388",1273,DB01175,Escitalopram
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,387,7523,DB01175,Escitalopram
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,99.2,7524,DB01175,Escitalopram
,19841156,Apparent clearance (CL/F),"Apparent clearance (CL/F) and volume of distribution (V/F) for escitalopram without including any covariates in the patient population were 23.5 L/h and 884 L, respectively.","Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841156/),[l] / [h],23.5,13796,DB01175,Escitalopram
,19841156,volume of distribution (V/F),"Apparent clearance (CL/F) and volume of distribution (V/F) for escitalopram without including any covariates in the patient population were 23.5 L/h and 884 L, respectively.","Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841156/),l,884,13797,DB01175,Escitalopram
,12387707,half-life,"Escitalopram has linear pharmacokinetics, so that plasma levels increase proportionately and predictably with increased doses and its half-life of 27 - 32 h is consistent with once-daily dosing.",Escitalopram. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12387707/),h,27 - 32,17299,DB01175,Escitalopram
,28673858,permeation amount,"The optimized patch prepared with ESP-BA showed zero-order skin permeation profile and a satisfied permeation amount of three days (1059±104.9μg/cm2) in vitro, which also showed a steady-state drug plasma concentration lasting 36h in vivo and the Cmax was significantly controlled compared with the control group.","Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673858/),[μg] / [cm2],105,22500,DB01175,Escitalopram
,28673858,steady-state drug plasma concentration,"The optimized patch prepared with ESP-BA showed zero-order skin permeation profile and a satisfied permeation amount of three days (1059±104.9μg/cm2) in vitro, which also showed a steady-state drug plasma concentration lasting 36h in vivo and the Cmax was significantly controlled compared with the control group.","Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673858/),h,36,22501,DB01175,Escitalopram
,21883384,half-life of effect-delay,"The heart rate corrected QT interval (QT(c) ) was linearly dependent on predicted escitalopram concentration [slope = 87ms/(mgl(-1) )], using a hypothetical effect-compartment (half-life of effect-delay, 1.0h).",Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883384/),h,1.0,27818,DB01175,Escitalopram
,21083123,flow rate,"After liquid-liquid extraction, the compounds were separated on a Vydac(®) C18 monomeric column (250 × 4.6 mm inner diameter × 5-µm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min(-1).",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[ml] / [min],1.0,31284,DB01175,Escitalopram
,21083123,maximum concentration,"After talinolol (10 mg kg(-1)) was given orally, the maximum concentration and the AUC(0-∞) were 341.8 ± 99.4 ng ml(-1) and 976.26 ± 173.37 ng h ml(-1), respectively.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[ng] / [ml],341.8,31285,DB01175,Escitalopram
,21083123,AUC(0-∞),"After talinolol (10 mg kg(-1)) was given orally, the maximum concentration and the AUC(0-∞) were 341.8 ± 99.4 ng ml(-1) and 976.26 ± 173.37 ng h ml(-1), respectively.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[h·ng] / [ml],976.26,31286,DB01175,Escitalopram
,21083123,oral bioavailability,The oral bioavailability was approximately 52.14 ± 9.26%.,Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),%,52.14,31287,DB01175,Escitalopram
,21083123,analysis time,"The advantages of our method are a small sample volume (200 µl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),min,13.5,31288,DB01175,Escitalopram
,19033124,flow rate,"The Agilent ZORBAX SB-C18 (3.5 microm,2.1 x 150 mm) was used as the analytical column with acetonitrile-NH4AC buffer (70:30, V/V) as the mobile phase at the flow rate of 0.3 ml/min.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),[ml] / [min],0.3,52426,DB01175,Escitalopram
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,325.4,52427,DB01175,Escitalopram
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,109.4,52428,DB01175,Escitalopram
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,64.98,52429,DB01175,Escitalopram
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,78.72,52430,DB01175,Escitalopram
,33647579,maximal QT prolongation,The average estimated maximal QT prolongation was 5.4 ms (range: 1.9-7.6 ms).,Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33647579/),ms,5.4,52612,DB01175,Escitalopram
,33647579,equilibrium half-life,The equilibrium half-life of delayed QT prolongation was 1.9 h.,Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33647579/),h,1.9,52613,DB01175,Escitalopram
,17014998,efficacy (I(max)),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],0.9,70262,DB01175,Escitalopram
,17014998,potency (IC(50)),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],4.4,70263,DB01175,Escitalopram
,17014998,EC(50),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],30,70264,DB01175,Escitalopram
,16291715,systemic clearance,"After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),[l] / [h],31,79113,DB01175,Escitalopram
,16291715,volume of distribution,"After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),l,"1,100",79114,DB01175,Escitalopram
,16291715,half-lives,"The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),h,27,79115,DB01175,Escitalopram
,16291715,half-lives,"The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),h,33,79116,DB01175,Escitalopram
,16291715,apparent volume of distribution,The apparent volume of distribution was around 20 L/kg.,The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),[l] / [kg],20,79117,DB01175,Escitalopram
,24937809,flow rate,"An isocratic mobile phase of acetonitrile: 5mM ammonium acetate: formic acid (35:65:0.1, v/v/v) was applied at a flow rate of 0.25mL/min.",A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),[ml] / [min],0.25,80785,DB01175,Escitalopram
,24937809,m,Detection was performed using multiple reaction-monitoring (MRM) modes at m/z 442.4→155.3 for vilazodone and m/z 325.1→109.0 for escitalopram.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),,442.4,80786,DB01175,Escitalopram
,24937809,total analysis time,The total analysis time was 2.2min.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),min,2.2,80787,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,23.7,81356,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,29.0,81357,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,5.24,81358,DB01175,Escitalopram
,16120067,"AUC(0, infinity)","Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),,1.51,81359,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,26.5,81360,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,34.8,81361,DB01175,Escitalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,8.3,81362,DB01175,Escitalopram
,22677485,flow rate,The mobile phase is acetonitrile-phosphate buffer (pH 3.6) 28:72% v/v at a flow rate of 1.0 mL/min.,High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),[ml] / [min],1.0,110028,DB01175,Escitalopram
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,79.32,110029,DB01175,Escitalopram
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,84.10,110030,DB01175,Escitalopram
,31144347,clearance,"The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively.",Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31144347/),[l] / [h],23.1,136128,DB01175,Escitalopram
,31144347,volume of distribution,"The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively.",Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31144347/),l,920,136129,DB01175,Escitalopram
,17654695,influx clearance into the brain,"The modelling resulted in an estimated influx clearance into the brain of 535 microl/min/g brain, resulting in an unbound brain-to-plasma AUC ratio of 0.8 independent of escitalopram dose.",Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654695/),[μl] / [brain·g·min],535,140364,DB01175,Escitalopram
,17654695,unbound brain-to-plasma AUC ratio,"The modelling resulted in an estimated influx clearance into the brain of 535 microl/min/g brain, resulting in an unbound brain-to-plasma AUC ratio of 0.8 independent of escitalopram dose.",Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654695/),,0.8,140365,DB01175,Escitalopram
,17375980,elimination half-life,The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration.,The clinical pharmacokinetics of escitalopram. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),h,27-33,147053,DB01175,Escitalopram
,17375980,protein binding,Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs.,The clinical pharmacokinetics of escitalopram. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),%,56,147054,DB01175,Escitalopram
,17375980,apparent volume of distribution during the terminal phase after oral administration (V(z)/F),"It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L.",The clinical pharmacokinetics of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),l,1100,147055,DB01175,Escitalopram
,19537522,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[ng] / [ml],9.85,157337,DB01175,Escitalopram
,19537522,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[ng] / [ml],9.92,157338,DB01175,Escitalopram
,19537522,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],428.40,157339,DB01175,Escitalopram
,19537522,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],413.73,157340,DB01175,Escitalopram
,19537522,AUC(0-t),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],401.33,157341,DB01175,Escitalopram
,19537522,AUC(0-t),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],385.42,157342,DB01175,Escitalopram
,19537522,T(max),"The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,4.3,157343,DB01175,Escitalopram
,19537522,T(max),"The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,4.1,157344,DB01175,Escitalopram
,19537522,Plasma elimination half-lives (t 1/2),"Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,36.30,157345,DB01175,Escitalopram
,19537522,Plasma elimination half-lives (t 1/2),"Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,36.70,157346,DB01175,Escitalopram
,19179296,oral clearance (CL/F),Estimated oral clearance (CL/F) to escitalopram was statistically insensitive to reported dosing methods (MEMS vs patient reported: 25.5 [7.0%] vs 26.9 [6.6%] L/h).,The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),[l] / [h],25.5,169083,DB01175,Escitalopram
,19179296,oral clearance (CL/F),Estimated oral clearance (CL/F) to escitalopram was statistically insensitive to reported dosing methods (MEMS vs patient reported: 25.5 [7.0%] vs 26.9 [6.6%] L/h).,The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),[l] / [h],26.9,169084,DB01175,Escitalopram
,19179296,volume of distribution (V/F,"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,1000,169085,DB01175,Escitalopram
,19179296,volume of distribution (V/F,"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,767,169086,DB01175,Escitalopram
,19179296,absorption rate constant K(a),"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.74,169087,DB01175,Escitalopram
,19179296,absorption rate constant K(a),"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.51,169088,DB01175,Escitalopram
,19179296,V/F,"Furthermore, the parameters estimated from the MEMS method were similar to literature reported values for V/F ( approximately 1100 L) and K(a) ( approximately 0.8-0.9 h(-1)) arising from traditional pharmacokinetic approaches.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,1100,169089,DB01175,Escitalopram
,19179296,K(a),"Furthermore, the parameters estimated from the MEMS method were similar to literature reported values for V/F ( approximately 1100 L) and K(a) ( approximately 0.8-0.9 h(-1)) arising from traditional pharmacokinetic approaches.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.8-0.9,169090,DB01175,Escitalopram
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,276.2-216.2,169106,DB01175,Escitalopram
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,325.2-109.1,169107,DB01175,Escitalopram
,27209054,total run time,The total run time was 1.5 min.,UPLC-MS-MS Method for the Determination of Vilazodone in Human Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209054/),min,1.5,181804,DB01175,Escitalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,13.7,198581,DB01175,Escitalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.5,198582,DB01175,Escitalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.2,198583,DB01175,Escitalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,6.9,198584,DB01175,Escitalopram
,22628062,Cmax,"Mean±Standard deviation (SD) Cmax values were 18.89±5.06 ng/mL and 18.45±5.05 ng/mL for reference and test, respectively.",Bioequivalence of two formulations of escitalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[ng] / [ml],18.89,209730,DB01175,Escitalopram
,22628062,Cmax,"Mean±Standard deviation (SD) Cmax values were 18.89±5.06 ng/mL and 18.45±5.05 ng/mL for reference and test, respectively.",Bioequivalence of two formulations of escitalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[ng] / [ml],18.45,209731,DB01175,Escitalopram
,22628062,AUClast,AUClast was 577.16±196.20 ng · h/mL after the administration of the reference and 577.69±220.88 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],577.16,209732,DB01175,Escitalopram
,22628062,AUClast,AUClast was 577.16±196.20 ng · h/mL after the administration of the reference and 577.69±220.88 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],577.69,209733,DB01175,Escitalopram
,22628062,AUCinf,AUCinf was 595.66±203.80 ng · h/mL after the administration of the reference 596.19±235.47 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],595.66,209734,DB01175,Escitalopram
,22628062,AUCinf,AUCinf was 595.66±203.80 ng · h/mL after the administration of the reference 596.19±235.47 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],596.19,209735,DB01175,Escitalopram
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,90.45,229356,DB01175,Escitalopram
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,65.42,229357,DB01175,Escitalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264140,DB01175,Escitalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,98,264141,DB01175,Escitalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264142,DB01175,Escitalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,87,264143,DB01175,Escitalopram
